| 8 am | CMSC – ACTRIMS Donald Paty Memorial Lecture |
| Pros and cons of stem cell therapy Neil Scolding, PhD, FRCP- University of Bristol |
|
| 9 – 10:30 am | Session 1: Cell Replacement and Repair Moderators: Mark Freedman, MD, and Emmanuelle Waubant, MD, PhD |
| 9 am | Neural stem cells as instructors of repair mechanisms Stefano Pluchino, MD, PhD – IRCCS San Raffaele |
| 9:30 am | Stimulation of endogenous repair Tanja Kuhlmann, MD – University Hospital Muenster |
| 10 am | Roundtable Discussion/Q&A |
| 10:15 am | Coffee Break |
| 10:30 am – 12 pm | Session 2: Basic and Clinical Issues in Multiple Sclerosis Research Moderators: Christopher Bever, MD, MBA, and Peter Calabresi, MD |
| 10:30 am | Oral teriflunomide added to interferon-beta in relapsing multiple sclerosis patients: 1-year safety and efficacy results Mark S. Freedman, MD—The Ottawa Hospital |
| 10:45 am | Quantitative MRI characteristics of pediatric multiple sclerosis Tanuja Chitnis, MD—Massachusetts General Hospital, Boston |
| 11 am | Noninvasive differentiation of co-existing inflammation, axonal injury, and demyelination in the mouse corpus callosum Yong Wang, PhD—Washington University School of Medicine, St. Louis |
| 11:15 am | Regulation of the mode of t lymphocyte migration through the choroid plexus epithelium by epithelial v-like antigen Michael Carrithers, MD, PhD—University of Wisconsin-Madison |
| 11:30am | Cell type-specific responses to IFN-beta: implications for understanding the mechanism of IFN-beta therapy in multiple sclerosis Anette H. H. van Boxel-Dezaire, PhD—Cleveland Clinic Foundation |
| 11:45 am | Improving the recognition and management of mental health problems in persons with multiple sclerosis David Rintell, EdD—Partners Multiple Sclerosis Center, Boston |
| 12 – 1 pm | Lunch |
| 1 – 2 pm | Poster Session with Authors Present |
| 2 – 3:30 pm | Session 3: Risk Management Moderators: Aaron Miller, MD, and Jerry Wolinsky, MD |
| 2 pm | Risk management: an FDA perspective Russell Katz, MD – US Food and Drug Administration |
| 2:30 pm | Balancing benefit and risk from the patient’s perspective Michael Kattan, PhD – Cleveland Clinic |
| 3 pm | Risk perception about progressive multifocal leukoencephalopathy in natalizumab-treated patients and their neurologists Sascha Köpke, PhD—University of Hamburg |
| 3:15 pm | Roundtable Discussion/Q&A |
| 3:30 pm | Coffee Break |
| 3:45 – 5 pm | Session 4: Complications of Potent Immunosuppressive Agents in MS Moderators: Jeffrey Cohen, MD, and Robert Naismith, MD |
| 3:45 pm | Potent immunomodulation in MS: promise and problems (opportunistic infections, malignancies, autoimmunity) Richard Ransohoff, MD- Cleveland Clinic |
| 4:15 pm | Update: clinical features of PML David Clifford, MD- Washington University School of Medicine, St. Louis |
| 4:45 pm | Roundtable Discussion/Q&A |
| 5 pm | Closing Remarks |
| Friday, June 4 | |
| 8 am – 4 pm | CMSC John Whitaker Research Track |
| 6:30 pm – 8 pm | Joint CMSC-ACTRIMS Dinner and Poster Session with Authors Present |
| Saturday, June 5 | ACTRIMS |
| 7 am – 7:45 am | Speakers Breakfast (invitation only) |
| 8 am – 9 am | CMSC-ACTRIMS Donald Paty Memorial Research Lecture |
| 9 am – 12 pm | ACTRIMS General Session |
| 12 pm – 2 pm | Lunch and ACTRIMS Poster Session with Authors Present |
| 2 pm – 5 pm | ACTRIMS General Session (cont.) |
| 5 pm – 6 pm | ACTRIMS Steering Committee meeting (invitation only) |
